This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Merck (MRK) This Earnings Season?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Glaxo (GSK) Misses on both Earnings and Revenue in Q1
by Zacks Equity Research
Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
Sanofi to Divest European Generic Unit, Streamline Business
by Zacks Equity Research
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
by Zacks Equity Research
Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
by Zacks Equity Research
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.
Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
by Zacks Equity Research
Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
What All Investors Should Know about Trade Deficits and Recessions
by Tracey Ryniec
What's the trade deficit really about? And what are the key signals that may alert investors to an upcoming recession?
Merck's Keytruda Offers Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.
4 Drug/Biotech Stocks to Buy Ahead of World Health Day
by Indrajit Bandyopadhyay
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
Novartis Announces Data on Cardiovascular Drug Entresto
by Zacks Equity Research
Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.
Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study
by Zacks Equity Research
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?
by Zacks Equity Research
As GlaxoSmithKline (GSK) starts a strategic review of Horlicks and other smaller nutrition products, a number of companies in the food & beverage industry are waiting to scoop it up.
Puma's Shares Fall This Year Post a Solid 2017: Here's Why
by Zacks Equity Research
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Company News For Mar 28, 2018
by Zacks Equity Research
Companies in the news are: RHT,MKC,INFO,GSK,NVS
Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV
by Zacks Equity Research
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Pfizer's Chantix Fails in Phase IV Study in Young Smokers
by Zacks Equity Research
Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.
Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod
by Zacks Equity Research
Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.
GlaxoSmithKline Initiates Phase III Combo Study on Benlysta
by Zacks Equity Research
GlaxoSmithKline (GSK) initiates a phase III study evaluating Benlysta in combination with Rituxanin adult patients with systemic lupus erythematosus.
Pfizer's Xtandi Label Expansion Filing Gets Priority Review
by Zacks Equity Research
FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.